Schemia/reperfusion injury: Impact of erythropoietin

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 11, 2012, Pages 1535-1543

  Hussein, Abdel Aziz M ^a   Barakat, Nashwa ^b   Awadalla, Amira ^b   Shokeir, Ahmed A ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Erythropoietin; Haemodynamics; Ischemia reperfusion injury; Rats

Indexed keywords

ACETYLCHOLINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; ERYTHROPOIETIN; NITRIC OXIDE DONOR; NOS3 PROTEIN, RAT; PROTECTIVE AGENT; RECOMBINANT PROTEIN; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FRACTIONAL SODIUM EXCRETION; HEMATOCRIT; HISTOPATHOLOGY; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY PARENCHYMA; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; MALE; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SODIUM EXCRETION; URINE VOLUME; VASODILATATION; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; DRUG RESISTANCE; ENZYME INDUCTION; ENZYMOLOGY; GENETICS; HEMODYNAMICS; HYPOTENSION; ISCHEMIA; KIDNEY; KIDNEY CIRCULATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT; THORACIC AORTA; VASCULAR RESISTANCE; VASCULARIZATION;

ANIMALS; AORTA, THORACIC; DRUG RESISTANCE; ENZYME INDUCTION; ERYTHROPOIETIN; HEMATINICS; HEMODYNAMICS; HYPOTENSION; ISCHEMIA; KIDNEY; MALE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE III; PROTECTIVE AGENTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RENAL CIRCULATION; REPERFUSION INJURY; VASCULAR RESISTANCE; VASODILATION; VASODILATOR AGENTS;

EID: 84870203557     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/y2012-120     Document Type: Article

References (37)

1. Aktaş, A., Aras, M., Çolak, T., Gencǒglu, A., and Karakayali, H. 2006. Comparison of Tc-99m DTPA and Tc-99m MAG3 perfusion time-activity curves in patients with renal allograft dysfunction. Transplant. Proc. 38(2): 449-453. doi:10.1016/j.transproceed. 2006.01.006. PMID:16549144.
2. Azzadin, A., Bialkowska, A., Buczko, W., Malyszko, J., Kalinowski, M., and Mysliwiec, M. 1992. Serotonergic mechanism of erythropoietin-induced hypertension. Nephrol. Dial. Transplant. 7(8): 882-883. PMID:1325627.
3. Bahlmann, F.H., Kielsteil, J.T., Menne, J., de Groot, K., Haller, H., and Fliser, D. 2006. Erythropoietin counteracts the renal hemodynamic effects of ADMA. Vascul. Pharmacol. 45(3): e49-e50. doi:10.1016/j.vph.2006.08.167.
4. Bode-Böger, S.M., Böger, R.H., Kuhn, M., Radermacher, J., and Frölich, J.C. 1992. Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J. Cardiovasc. Pharmacol. 20: S25-S28. doi:10.1097/00005344-199204002-00009. PMID:1282978.
5. Burger, D., Lei, M., Geoghegan-Morphet, N., Lu, X., Xenocostas, A., and Feng, Q. 2006. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc. Res. 72: 51-59.
6. Carlini, R., Obialo, C.I., and Rothstein, M. 1993. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am. J. Hypertens. 6(2): 103-107. PMID:8471228.
7. Carlini, R.G., Gupta, A., Liapis, H., and Rothstein, M. 1995. Endothelin_ 1 release by erythropoietin involves calcium signaling in endothelial-cells. J. Cardiovasc. Pharmacol. 26(6): 889-892. doi: 10.1097/00005344-199512000-00006. PMID:8606524.
8. D'Uscio, L.V., Smith, L.A., Santhanam, A.V., Richardson, D., Nath, K.A., and Katusic, Z.S. 2007. Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension, 49: 1142-1148.
9. Gambone, L.M., Murray, P.A., and Flavahan, N.A. 1997. Synergistic interaction between endothelium-derived NO and prostacyclin in pulmonary artery: Potential role for K-ATP(+) channels. Br. J. Pharmacol. 121(2): 271-279. doi:10.1038/sj.bjp.0701082. PMID: 9154337.
10. Hayashi, Y., Sawa, Y., Fukuyama, N., Nakazawa, H., and Matsuda, H. 2001. Inducible nitric oxide production is an adaptation to cardiopulmonary bypass-induced inflammatory response. Ann. Thorac. Surg. 72(1): 149-155. doi:10.1016/S0003-4975(01)02637-6. PMID:11465170.
11. Henry, D.H., Bowers, P., Romano, M.T., and Provenzano, R. 2004. Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch. Intern. Med. 164(3): 262-276. doi:10.1001/archinte.164.3.262. PMID:14769622.
12. Huang, C.L., Davis, G., and Johns, E.J. 1993. Role of haematocrit in mediating the actions of chronic erythropoietin treatment on blood-pressure and renal hemodynamics in the rat. Clin. Sci. 85(6): 717-724. PMID:8287665.
13. Hussein, A.E.-A.M., Shokeir, A.A., Sarhan, M.E., El-Menabawy, F.R., Abd-Elmoneim, H.A., El-Nashar, E.M., and Barakat, N.M. 2011. Effects of combined erythropoietin and epidermal growth factor on renal ischaemia/ reperfusion injury: a randomized experimental controlled study. BJU Int. 107(2): 323-328. doi:10.1111/ j.1464-410X.2010.09328.x. PMID:20346036.
14. ILAR (Institute of Laboratory Animal Resources). 1996. Guide for the Care and Use of Laboratory Animals. NIH Publication No. 85-23 (revised 1996). National Academy Press, Washington, D.C. Available from www.nap.edu/openbook.php?record_id=5140.
15. Kubes, P., Suzuki, M., and Granger, D.N. 1991. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U.S.A. 88(11): 4651-4655. doi:10.1073/pnas.88.11.4651. PMID:1675786.
16. Lin, E., and Alavi, A. 1998. Significance of early tubular extraction in the first minute of Tc-99m MAG3 renal transplant scintigraphy. Clin. Nucl. Med. 23(4): 217-222. doi:10.1097/00003072- 199804000-00005. PMID:9554192.
17. Livak, K.J., and Schmittgen, T.D. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods, 25(4): 402-408. PMID:11846609.
18. Lopau, K., Hefner, L., Bender, G., Heidbreder, E., and Wanner, C. 2001. Haemodynamic effects of valsartan in acute renal ischaemia/ reperfusion injury. Nephrol. Dial. Transplant. 16(8): 1592-1597. doi:10.1093/ndt/16.8.1592. PMID:11477160.
19. Matsuzaki, T., Watanabe, H., Yoshitome, K., Morisaki, T., Hamada, A., Nonoguchi, H., et al. 2007. Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced qacute renal failure. Kidney Int. 71(6): 539-547. doi:10.1038/ sj.ki.5002104. PMID:17245393.
20. Muntzel, M., Hannedouche, T., Lacour, B., and Drüeke, T. 1992. Effect of erythropoietin on hematocrit and blood pressure in normotensive and hypertensive rats. J. Am. Soc. Nephrol. 3(2): 182-187. PMID:1391718.
21. Ono, K., and Hisasue, Y. 1992. The rate of increase in hematocrit, humoral vasoactive substances and blood pressure changes in hemodialysis patients treated with recombinant human erythropoietin or blood transfusion. Clin. Nephrol. 37(1): 23-27. PMID: 1531789.
22. Ortiz, P.A., and Garvin, J.L. 2003. Cardiovascular and renal control in NOS-deficient mouse models. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284(3): R628-R638. PMID:12571071.
23. Radomski, M.W., Palmer, R.M., and Moncada, S. 1990. An Larginine/ nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad. Sci. U.S.A. 87(13): 5193-5197. doi:10.1073/pnas.87.13.5193. PMID:1695013.
24. Santhanam, A.V., Smith, L.A., Nath, K.A., and Katusic, Z.S. 2006. In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries. Am. J. Physiol.Heart Circ. Physiol. 291: H781-H786.
25. Satoh, M., Fujimoto, S., Haruna, Y., Arakawa, S., Horike, H., Komai, N., et al. 2005. NAD (P) H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am. J. Physiol. Renal Physiol. 288(6): F1144-F1152. doi:10.1152/ajprenal.00221.2004. PMID: 15687247.
26. Schrier, R.W., Wang, W., Poole, B., and Mitra, A. 2004. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J. Clin. Invest. 114(1): 5-14. PMID:15232604.
27. Sølling, C., Christensen, A.T., Krag, S., Frøkiaer, J., Wogensen, L., Krog, J., and Tønnesen, E.K. 2011. Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischemia-reperfusion injury. Acta Anaesthesiol. Scand. 55(2): 185-195. doi:10.1111/j.1399-6576.2010.02369.x. PMID: 21226860
28. Spandou, E., Tsouchnikas, I., Karkavelas, G., Dounousi, E., Simeonidou, C., Guiba-Tziampiri, O., and Tsakiris, D. 2006. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol. Dial. Transplant. 21(2): 330-336. doi:10.1093/ndt/gfi177. PMID:16221709.
29. Sutton, T.A., Fisher, C.J., and Molitoris, B.A. 2002. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int. 62(5): 1539-1549. doi:10.1046/j.1523-1755.2002.00631.x. PMID:12371954.
30. Toba, H., Nakashima, K., Oshima, Y., Kojima, Y., Tojo, C., Nakano, A., et al. 2010. Erythropoietin prevents vascular inflammation and oxidative stress in subtotal nephrectomized rat aorta beyond haematopoiesis. Clin. Exp. Pharmacol. Physiol. 37(12): 1139-1146. doi:10.1111/j.1440-1681.2010.05445.x. PMID:20819095.
31. Uchino, S., Kellum, J.A., Bellomo, R., Doig, G.S., Morimatsu, H., Morgera, S., et al. (Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators). 2005. Acute renal failurein critically ill patients: a multinational, multicenter study. JAMA, 294(7): 813-818. doi:10.1001/jama.294.7.813. PMID: 16106006.
32. Vaziri, N.D. 1999. Mechanism of erythropoietin-induced hypertension. Am. J. Kidney Dis. 33(5): 821-828. doi:10.1016/S0272-6386(99)70413-0. PMID:10213636.
33. Vaziri, N.D. 2001. Cardiovascular effects of erythropoietin and anemia correction. Curr. Opin. Nephrol. Hypertens. 10(5): 633-637. doi:10.1097/00041552-200109000-00013. PMID:11496057.
34. Vaziri, N.D., Zhou, X.J., Smith, J., Oveisi, F., Baldwin, K., and Purdy, R.E. 1995. In vivo and in vitro pressor effects of erythropoietin in rats. Am. J. Physiol. 269(6): F838-F845. PMID:859 4878.
35. Vaziri, N.D., Zhou, X.J., Naqvi, F., Smith, J., Oveisi, F., Wang, Z.Q., and Purdy, R.E. 1996. Role of nitric-oxide resistance in erythropoietin-induced hypertension in rats with chronic-renalfailure. Am. J. Physiol. 271(1): E113-E122.PMID:8760088.
36. Wada, Y., Matsuoka, H., Tamai, O., Kohno, K., Okuda, S., and Imaizumi, T. 1999. Erythropoietin impairs endothelium-dependent vasorelaxation through cyclooxygenase-dependent mechanisms in humans. Am. J. Hypertens. 12(10): 980-987. doi:10.1016/S0895-7061(99)00081-3. PMID:10560784.
37. Xenocostas, A., Cheung, W.K., Farrell, F., Zakszewski, C., Kelley, M., Lutynski, A., et al. 2005. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur. J. Clin. Pharmacol. 61(3): 189-195. doi:10.1007/s00228-005-0896-7. PMID:15776276.